PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DX23FKVHL4559568753!botulinum TOX TYP a 1s — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DX15D9628. PoP ended Feb 1, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Dms Pharmaceutical Group Inc

Recipient

Feb 1, 2023

PoP end

$226K

Obligated

$226K

Potential

325411

NAICS

6515

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal

Contract numberSPE2DX23FKVHL

Also listed asSPE2DX15D9628-SPE2DX23FKVHL

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentDms Pharmaceutical Group Inc

CAGE1UNB0

UEIPX72BSBQTKJ3

NAICS325411

No full NAICS 325411 intel page yet. Browse NAICS intelligence

PSC6515

Parent IDIQ / IDVSPE2DX15D9628

Place of performancePARK RIDGE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJan 11, 2023

PoP end (current)Feb 1, 2023

Obligated$226K

Current value$226K

Potential value$226K

4559568753!BOTULINUM TOX TYP A 1S is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $226K ($226K obligated). Current period of performance ends Feb 1, 2023. Place of performance: PARK RIDGE IL.

Recompete timing

Public

● Past PoP end (1297 days ago)

Current PoP ended Feb 1, 2023 (1297 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies

Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0120

8511978882!OTHER MEDICAL

$248K

Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DX23FKVHL?

SPE2DX23FKVHL (4559568753!botulinum TOX TYP a 1s) is a Dla Troop Support award with a potential value of $226K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DX23FKVHL?

Dla Troop Support awarded SPE2DX23FKVHL to Dms Pharmaceutical Group Inc (potential $226K).

Who is the incumbent on SPE2DX23FKVHL?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Feb 1, 2023.

When does Dms Pharmaceutical Group Inc’s SPE2DX23FKVHL come up for recompete?

SCOUT tracks a period-of-performance end of Feb 1, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Jan 11, 2023